Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.

The remaining 94,000 doses of state-funded influenza vaccine from a batch found with a discolored dose earlier this month ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

The FDA has approved updated labeling for Flublok (influenza vaccine) to include new safety data involving pregnant individuals.

Key targets of the programme are elderly people and children. This programme is a part of Sanofi's commitment to improving ...

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Birds and humans have different types of receptors in their respiratory tract that flu viruses attach to, like a lock ...